immunology/inflammation capabilities - cellomatics bio · 2018-10-14 · whole blood assay (wba)...
TRANSCRIPT
1CONFIDENTIAL
Immunology/Inflammation
Capabilities
■ Cellomatics Biosciences Ltd is a Specialised laboratory-based
Contract Research Organisation (CRO)
■ We support our customers in every aspect of their Preclinical in vitro
R&D studies
■ With an experienced team of scientists and clinical professionals, we
understand your requirements and can deliver innovative and
practical solutions
CONFIDENTIAL 2
Who are we?
Our team
3CONFIDENTIAL
Dr. Anushuya Tamang
Bioassay Study ScientistAnushuya holds a MSc in
Biotechnology , MRes in Cancer
Biology and PhD in Developmental
Biology. She has more than 6 years
experience in Molecular and Cellular
biology as well as Histology.
Dr. Federica Riu
Bioassay Study ManagerFederica holds a MSc in Cellular
Biology and a PhD in Clinical and
Experimental Microbiology. She has
over 10 years of experience in
Molecular, Cellular and Vascular
Biology, Microbiology and Stem Cells.
Dr. Shailendra Singh
Founder and CEOShailendra’s scientific background
lies in target identification and
validation for the management of
respiratory diseases. Overall, he has
over 14 years of experience in
research and development within the
academia and industry together with
clinical diagnostics.
Camille Hetez, MSc
Head business development Camille holds a MSc in Biotechnology
Engineering from Paris and an MBA
Entrepreneurship. She has experience
in various Business Development
positions and also 3 years experience
as a Co-founder and CEO in a
innovative biotechnology company.
4
Area of expertise
RespiratoryImmunology CardiovascularOncology
CONFIDENTIAL
5
Overview of our services
Toxicity assays
Target validation & qualification
Biomarker assays
Multiplex nucleic acid & proteins test
In vitro Cell-based assays
CONFIDENTIAL
6
Receive your request
Understand your need
Personalized quotation
Sign contract
Weekly project
updates
Deliver High quality report
We are committed to
1. Understanding your needs and tailoring
our services to meet your requests
2. Meeting your timelines
3. Providing interactive and efficient
customer support
4. Delivering high quality services at a very
cost effective price
CONFIDENTIAL
Our approach
■ Immunology is the study of the immune response of a body towards
antigens.
■ There are two types of immune-responses:
– Innate (in-born)
– Adaptive (acquired)
■ They can be further divided into: Humoral and Cellular
■ Humoral immunity is carried out by the production of antibodies by B
lymphocytes (B-cells).
■ Cellular immunity is mediated by thymus derived lymphocytes (T-cells).
■ Both mechanisms recruit other cells of the immune system, such as
macrophages, dendritic cells, to further eliminate the antigens.
CONFIDENTIAL 7
Immunology
TYPE DESCRIPTION METHOD END-POINT DATA
HUMORAL
IMMUNITY
Antibody Production
ELISA Colorimetric Quantitative
Luminex Bead-based Quantitative
cell-ELISA Colorimetric Quantitative
Macrophage
Endocytosis Fluorometric Quantitative
Phagocytosis Colorimetric Quantitative
PeroxidaseColorimetric/
FluorometricQuantitative
CONFIDENTIAL 8
Analytical and Functional Assays
CONFIDENTIAL 9
Analytical and Functional Assays
CELLULAR
IMMUNITY
CytokinesELISA Colorimetric Quantitative
Luminex Bead-based Quantitative
Cell Surface antigens
ELISA Colorimetric Quantitative
Immunofluorescent
stainingImaging Qualitative
cell-ELISA Colorimetric Quantitative
Proliferation BrdU incorporation Imaging Qualitative
Toxicity assays:
• Antibody dependent cellular cytotoxicity (ADCC)
• Antibody-dependent cellular phagocytosis (ADCP)
• Complement-dependent cytotoxicity (CDC)
Cytotoxicity Assay Chemiluminescence Quantitative
Cell viability, apoptosis / necrosis Colorimetric/Fluorometric Quantitative
Chemotaxis Boyden chamber Colorimetric/Fluorometric Quantitative
Macrophage
Endocytosis Fluorometric Quantitative
Phagocytosis Colorimetric Quantitative
Peroxidase Colorimetric/Fluorometric Quantitative
TYPE DESCRIPTION METHOD END-POINT DATA
■ Assays can be performed with combination of cell co-cultures:
– Such as leukocytes, fibroblasts, macrophages etc.
– Primary or immortalised cell lines.
■ We also assist in isolating the primary cells in-house, such as PBMCs,
eosinophils, neutrophils, lymphocytes etc.
CONFIDENTIAL 10
Functional Assays
■ Proliferation/Apoptosis: BrdU incorporation, Alamar Blue, Ki-67
Caspase 3/7, TUNEL assay
■ Cytotoxicity: MTT assay, mitochondrial damage, genotoxicity, LDH
■ Migration: Boyden chamber, scratch assay, Matrigel degradation,
haptotaxis assay
■ Cell adhesion assay: to test the ability of immune cells to adhere to
specific extracellular matrix proteins.
CONFIDENTIAL 11
Proliferation/apoptosis, cytotoxicity, migration
■ Macrophage Activation
– Blood samples are collected from healthy donors and cells are isolated.
– Isolated cells will then be exposed either to the CLIENT’s proprietary molecules
for defined timings or to control Antibody, along with a positive (i.e. LPS) or
negative (to be defined by CLIENT) control.
– Stimulated cells will be then processed for the following activation parameters:
■ Molecular Biology
– Quantitative gene expression of target inflammatory genes
■ Biochemical Characterization
– Inflammatory cytokine production (i.e. IL-1α, IL-1β, IL-2, IL-4, IL-6, IL-10, VEGF)
– Total ROS production
– Phagocytic activity
– Mitochondrial damage
– Cell viability and toxicity
CONFIDENTIAL 12
Immune Cell Activation Assays
■ Mast Cells Activation
– HBEC/BEAS 2B and HMC-1 Co-culture model
■ Sensitisation using either 2.5 µg/ml human IgE or Calcium Ionophore to induce
mast cell degranulation
■ Mast cell activation will be monitored by quantitative analysis of allergen-induced
histamine release. In particular, the following parameters will be measured:
– Release of β−hexosaminidase
– Mast cell degranulation assays
■ Measure the mast cell tryptase activity using a spectrophotometric method as an
indicator of mast cell degranulation
■ Measure the release of other mediators of allergy and inflammation including
histamine, lipoxin A4 by immunoassays
CONFIDENTIAL 13
Immune Cell Activation Assays
■ B lymphocytes IgE release assay
– Stimulation of B lymphocyte cell line with IL4, IL5 and IL13
– Measure IgE release by immunoassays
CONFIDENTIAL 14
Immune Cell Activation Assays
■ Intestinal epithelial cell lines
– Caco-2, HT-29, T-84
■ Treatment with pro-inflammatory compounds
– LPS, IL-1β
■ End points
– Release of pro-inflammatory markers
■ e.g. IL8, TNF-alpha: ELISA, Multiplex immunoassay
– Rearrangement of tight junction proteins
■ e.g. ZO-1, occludin & claudin-1: Immunofluorescence (IF)
– Increased mucus production
■ Mucin staining: Periodic acid/ Schiff reagent; Mucus staining: Alcian blue
CONFIDENTIAL 15
Monolayer: Single-culture
Monolayer: Single culture
■ Intestinal epithelial cell lines
– Caco-2, HT-29, T-84
■ Treatment with pro-inflammatory compounds
– LPS, IL-1β
■ End points
CONFIDENTIAL 16
Monolayer: Trans-well Single-culture
- Release of pro-inflammatory markers:
e.g. IL8, TNF-alpha: ELISA, Multiplex
immunoassay
- Increased mucus production
Mucin staining: Periodic acid/ Schiff
reagent; Mucus staining: Alcian blue
- Rearrangement of tight junction
proteins
e.g. ZO-1, occludin & claudin-1:
Immunofluorescence (IF)
- Reduction of barrier function
TEER
Fluorescein transport
Monolayer: Trans-well Single culture
■ Intestinal epithelial cell lines
– Caco-2, HT-29, T-84
■ Co-culture
– Human blood-derived macrophages and dendritic cells, PBMC
■ Treatment with pro-inflammatory compounds
– LPS, IL-1β
■ End points
CONFIDENTIAL 17
3-D: Trans-well Co-culture
- Release of pro-inflammatory markers:
e.g. IL8, TNF-alpha: ELISA, Multiplex
immunoassay
- Increased mucus production
Mucin staining: Periodic acid/ Schiff
reagent; Mucus staining: Alcian blue
- Rearrangement of tight junction
proteins
e.g. ZO-1, occludin & claudin-1:
Immunofluorescence (IF)
- Reduction of barrier function
TEER
Fluorescein transport
3-D: Trans-well Co-culture
BIOMARKERS
CONFIDENTIAL 18
■ The regulation and initiation of immune
response involves multiple changes in gene and
protein expressions.
■ These variations can be monitored to
investigate the progression of diseases and
validate drug treatment.
■ Some of the Biomarker panels available for
Luminex Platform:
– Immunology
– Inflammation
– Cytokines/Chemokines
– Sepsis
– Skin
CONFIDENTIAL 19
Biomarker Analysis
ASSAY
CATEGORYASSAY
Protein
expression
ELISA
Multiplex Immunoassays
(Luminex Platform)
Gene expression
PCR
RT-PCR
Multiplex Nucleic Acid Testing
(Luminex Platform)
LocalisationImmunohistochemistry (IHC)
Immunocytochemistry (ICC)
Different types of biomarker assays
■ Pathway activation biomarkers
– Measure phosphorylation of downstream signalling events
■ Multiplexing immunoassays
■ Western Blot
■ In-Cell ELISA
■ Disease Biomarkers
– Measure release of cytokines, chemokines, growth factors and inflammatory
mediators (mRNA and protein)
■ Multiplexing immunoassays
■ ELISA
CONFIDENTIAL 20
Immunology/Inflammation Assays
■ Advantages
– Multiplex Technology allows to detect up to 50 targets per well
– No need to process the samples
– No RNA isolation: no risk to loose material, RNA degradation, DNA
contamination
– No cDNA: some mRNA are low represented and difficult to retrotranscribe
– No PCR: low number transcript might be masked by high copies transcripts; no
requirement for specific primers
– High specificity of probes and antibodies.
– Large panel of targets and species
– Plated and panels customizable
CONFIDENTIAL 21
Multiplex gene assays
CONFIDENTIAL 22
Inflammatory Pathologies
■ Whole blood assay (WBA) (Laufer et al) - Among several in vitro testing
systems the whole blood assay (WBA) is a well-known method to
examine non-steroidal anti-inflammatory drugs (NSAIDs) in view of
their potency to inhibit COX activity.
– Measurement of COX-1 activity in whole blood:
■ Using heparinised blood
■ Using coagulated blood
– Measurement of COX-2 activity in whole blood
CONFIDENTIAL 23
In vitro models for COX assays - Pain/Inflammation
■ Cell-based models for COX assays
– Specific Cell lines
■ A549, a human epithelial carcinoma cell line (ECACC Ref. No. 86012804),
expresses COX-2 when exposed to IL-1β (Mitchell et al., 1994). Production of PGE2
by this cell line can therefore be used as an index of COX-2 activity.
– Other cell lines where COX inhibition can be investigated:
■ COS-1 cells
■ CHO cells
■ RBL-1 cells
■ melanoma (MeLiM)
■ histiocytic lymphoma cell line U937
■ prostate carcinoma line PC3
■ P493-6, a B cell line carrying a conditional, tetracyclin-regulated MYC gene bovine
aortic endothelial cells.
CONFIDENTIAL 24
In vitro models for COX assays - Pain/Inflammation
■ Cell-based models for COX assays
– Intact cells: Detection of PGE2 or TXB2 levels in the cell culture medium.
■ COX-1 activity
■ COX-2 activity
– Cell Lysate preparation: Detection of COX activity in the cell lysates
CONFIDENTIAL 25
In vitro models for COX assays - Pain/Inflammation
■ A chronic or recurrent inflammatory conditions of the colon and small
intestine (Crohn's Disease and Ulcerative Colitis).
Causes: Defects in the intestinal barrier
■ Impaired immune function
■ Genetic predispositions (e.g. NOD2 mutation)
■ Environmental factors
Characteristic:
Increased proinflammatory immune response to the commensal intestinal microbial flora.
■ Leads to increased permeability of the intestinal epithelial barrier.
■ Allows toxins and microbes to reach the underlying tissues.
■ Alterations in the mucosal architecture, e.g. transcellular bridge formation in epithelial cells
and goblet cell hyperplasia or hypertrophy or both.
CONFIDENTIAL 26
Inflammatory Bowel Disease (IBD)
CONFIDENTIAL 27
IBD cell models
CONFIDENTIAL 28
IBD – STUDY DESIGN EXAMPLE
CONFIDENTIAL 29
IBD – STUDY DESIGN EXAMPLE
IMMUNE PATHOLOGIES
CONFIDENTIAL 30
■ An inflammatory skin disorder,
triggered or exacerbated by a
number of genetic,
environmental, or immunological
factors.
■ Characterized by
– Hyperproliferation of keratinocytes
– Abnormal epidermal differentiation
– Infiltration of inflammatory cells
CONFIDENTIAL 31
Psoriasis
Mahajan R, Handa S. Pathophysiology of psoriasis. Indian J Dermatol Venereol Leprol 2013;79,
Suppl S1:1-9
■ Psoriasis initiation
– Keratinocyte & blood cell models – 3D, co-culture (keratinocytes + dermal
fibrobalsts)
– Proliferation (BrdU, MTT, Alamar Blue, Ki-67, Caspase3/7, TUNEL assay)
– Epidermal differentiation - Cultures of keratinocytes grown on filter at the
AirLiquid Interface
■ measure epidermal differentiation markers (involucrin, keratin10, keratin 14,
filaggrin)– mRNA and protein
– Membrane integrity assay
– LL-37 production by keratinocytes, macrophages & neutrophils (mRNA &
protein)
CONFIDENTIAL 32
In vitro assays - Psoriasis
■ Psoriasis progression
– T cell models (including T cells from psoriatic lesions)
■ Th17 cytokine production/release mRNA and protein)
– Granulocyte & monocyte/macrophage models
■ Pro-inflammatory cytokine production/release
CONFIDENTIAL 33
In vitro assays - Psoriasis
■ Psoriasis physiopathology
Keratinocytes & 3 D skin models (Cultures of keratinocytes grown on
filter at the AirLiquid Interface), co-culture models (keratinocytes +
dermal fibroblasts) induction by validated cytokine cocktails
– Modifications of epidermal differentiation and disease markers (involucrin,
keratin10, keratin 14, filaggrin; mRNA & protein)
– Antimicrobial peptide production/release (mRNA & protein)
– Membrane integrity assay
– Chemokine production/release (mRNA & protein)
– Cytokine signaling; STAT-3/STAT-1, MAPK, NFkB & other involved pathways
CONFIDENTIAL 34
In vitro assays - Psoriasis
■ Atopic Dermatitis - Also known as atopic eczema, is a chronic inflammatoryfamilial disease of the skin. It is characterized by an increased ability to formimmunoglobulin E and a tendency to develop other allergic conditions suchas allergic rhinitis and asthma.
■ Psoriasis - Psoriasis is an autoimmune disease in which the skin becomesinflamed, producing red, flaky areas. It affects 1-2% of the population and isthought to be caused by misguided T cell attacks on the skin.
■ Arthritis - is an umbrella term that describes a group of disorderscharacterized by joint inflammation involving the immune system andsudden, painful onset.
■ Asthma - Asthma is a form of bronchial disorder caused by inflammation ofthe bronchi. It is characterized by spasmodic contraction of airway smoothmuscle, difficulty breathing, wheezing and coughing.
■ Inflammatory Bowel Disease (IBD): Chronic or recurrent inflammatoryconditions of the colon and small intestine (Crohn’s Disease and UlcerativeColitis).
CONFIDENTIAL 35
Pathology involving immune system
■ Chronic, complex allergic inflammatory skin disease that affects 10-20% ofthe population
■ Initial immune response begins with the T helper (Th)2 response and is thenshifted to Th1 in the chronic phase.
■ Genetic background (e.g. mutations in filaggrin) and defective skin barrier -an additional risk factor for developing AD.
■ Barrier dysfunction exposes immune system cells to external allergens,eliciting an immune response.
■ Initiation and progression of this "Th2"-type dermatosis is under thedependence of the keratinocyte-derived cytokine: Thymic StromalLymphoprotein (TSLP). TSLP targets dendritic cells (DCs) and drives aspecific Th2 response.
■ AD physiopathology results in skin abnormalities, inflammation with IgE andhistamine production, erythema, eosinophilia, alopecia and itching.
CONFIDENTIAL 36
Atopic dermatitis (AD)
CONFIDENTIAL 37
Atopic dermatitis
▪ Carr WW. Topical calcineurin inhibitors for atopic dermatitis: review and treatment recommendations. Paediatr Drugs 2013;
15:303–10.
▪ Elias PM, Hatano Y, Williams ML. Basis for the barrier abnormality in atopic dermatitis: outside-inside-outside pathogenic
mechanisms. J Allergy Clin Immunol 2008; 121:1337–43.
■ AD initiation - Keratinocyte model
– Involves stimulation of cultured keratinocytes (NHEK) using a cocktail of
proinflammatory agents, including Poly(I:C) and (TNF)-a (Th1cytokine) Or
Poly(I:C), IL-4 and IL-13 (Th2 cytokines)
– Measure expression of TSLP, IL1α, IL18, IFNα2, IFNβ1, IL4R, IL8, MIP1α,
RANTES, MIP3α, MDC, CCL27, involucrin and filaggrin in stim vs unstim human
epidermal keratinocytes (NHEKs): Multiplex immunoassay/gene expression
– Measure anti-microbial peptides including cathelicidin, RNA SE7, S100A11,
psoriasin – immunoassays
– TLR3/RLRs signaling: NFkB, IRF3 translocation/ phosphorylation.
– JAK/STAT, PI3K signalling
CONFIDENTIAL 38
In vitro models
■ AD initiation - Atopic dermatitis reconstructed human epidermis model
(3D)
– Consists of normal, human-derived epidermal keratinocytes (NHEK) cultured on
specially prepared tissue culture inserts.
– Biology of whole-tissue models closely aligned with in vivo modelling than cell
culture alone
– Stimulated with Th2 cytokines IL-4 and IL-13, and the TLR ligands Poly (I:C) and
Pam3CKS4
– Measure expression of TSLP, IL1α, IL18, IFNα2, IFNβ1, IL4R, IL8, MIP1α,
RANTES, MIP3α, MDC, CCL27, involucrin and filaggrin in stim vs unstim human
epidermal keratinocytes (NHEKs): Multiplex immunoassay/gene expression
– Measure anti-microbial peptides including cathelicidin, RNA SE7, S100A11,
psoriasin – immunoassays
CONFIDENTIAL 39
In vitro models
■ AD progression - Adaptive immunity model (T cell models )
– Purifying human CD4+ lymphocytes from circulating peripheral blood
mononuclear cells isolated from healthy donors stimulated with staphylococcal
enterotoxin B (SEB)
– Measure expression of IL2, IL12, IL1β, TNFα, IL4, IL5, IL13, IL6, IL18, IL10,
IL17, IL31 (mRNA and protein by multiplexing)
■ AD progression - Innate immunity model (antimicrobial peptides)
– Stimulation of NHEK cells with IL1β
– Measure expression of cathelicidin antimicrobial peptide LL-37 (CAMP) and
human b-defensin (hBD)2
CONFIDENTIAL 40
In vitro models
■ AD progression - Monocyte-derived dendritic cell (MoDC) models
– Isolation and stimulation of dendritic cells with TSLP
– Measure TSLP-induced expression of activation markers: OX40L, MHCII, CD80,
CD86, CCL17, CCL22 (mRNA & protein by multiplex)
– TSLP signaling: STAT-5 phosphorylation (JAK-independent)
■ AD physiopathology - Mast cell model
– Stimulation of human mast cell (LUVA) by IgE
– Measure release of histamine and NGF
– Measure release of mast cell proteinases enzyme tryptase and chymase
CONFIDENTIAL 41
In vitro models
■ AD physiopathology - B cell model
– Stimulation of human B lymphocyte with IL4/IL13
– Measure release of IgE
■ AD physiopathology
– Cytokine signaling: STAT-6, MAPK & other involved pathways – Western Blotting
CONFIDENTIAL 42
In vitro models
CONFIDENTIAL 43
Example of AD initiation – Keratinocyte model
CONFIDENTIAL 44
Example of AD initiation – Keratinocyte model
CONFIDENTIAL 45
Example of AD pathophysiology – Mast cell model
“At Cellomatics Biosciences, we believe
in growing together. We welcome the
opportunity to partner and achieve
excellence together”
46
+44 (0) 115 7870081
www.cellomaticsbio.com
634 Innovation Centre
Biocity Nottingham NG1 1GF
Company Confidential